Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Theranos described a simple-sounding service: collect a small finger-stick blood sample, run it through a proprietary analyzer called the TSPU, Edison or miniLab, and return clinical test results. The official court and government record supports that high-level description, but not a detailed account of the device’s assay chemistry or engineering. It also documents a crucial gap between the promise and the operation: only twelve assays were ever run on the Edison, while many other tests used commercial analyzers, some modified by Theranos. Evidence summarized by the courts and the Department of Health and Human Services describes reliability, quality-control and throughput problems—not one proven technical defect that explains every failure.
What was Theranos’s blood-testing technology supposed to do?
Theranos promoted a proprietary clinical analyzer under several names: TSPU, Edison and miniLab. The proposed workflow was that a small blood sample collected by finger stick would be processed by Theranos’s system, which would then produce clinical test results. The attraction was the promise of obtaining a broad range of results from a small sample rather than relying on the conventional laboratory process Theranos sought to challenge.
That is the right level of technical detail to state confidently from the official record. The cited court and government materials describe the company’s claims and summarize evidence about how testing was conducted; they do not provide a full technical schematic or establish the underlying assay chemistry. They do not support a step-by-step description of how the Edison handled a sample, what reagents it used, or how particular tests were measured. Specific explanations along those lines would go beyond what those records establish.
The distinction matters because a testing service is more than a machine. A patient’s result depends on the test method, the instrument running it, the laboratory’s procedures and quality controls, and the handling and reporting of results. A claim about a compact analyzer cannot by itself show that every test offered by a company was performed on that analyzer or that the results were dependable.
#1 Best Overall
Could Theranos really run hundreds of tests from a finger prick?
The record supports a narrower answer than the headline promise suggested. A Ninth Circuit record reproduced in a 2026 Supreme Court appendix says Theranos developed 300 small-sample assays, but that only twelve assays were ever run on the Edison. Those are different measures: the first concerns assays the company said it developed; the second concerns assays actually run on the named device. The record does not say that the Edison performed all 300, nor does it establish that it handled most patient testing.
Other general chemistry tests were run on third-party machines, some modified by Theranos. The company therefore used a mixed testing operation: its own analyzer was part of the story, but commercial instruments also performed tests. The available record does not give a like-for-like numerical comparison of the Edison and conventional analyzers, or a complete count of how many patient tests were run on each type of machine.
| Question | What the official record supports | What it does not establish |
|---|---|---|
| How many small-sample assays did Theranos say it developed? | The Ninth Circuit record, as reproduced in a 2026 Supreme Court appendix, records a claim of 300. | That all 300 were run on the Edison or offered as validated Edison tests. |
| How many assays were ever run on the Edison? | Twelve, according to that appellate record. | That only twelve assays were ever developed, or that those twelve accounted for most of Theranos’s testing. |
| What ran other tests? | Commercial third-party instruments were used for other general chemistry tests; some were modified by Theranos. | A complete allocation of patient tests across proprietary and commercial machines. |
“Hundreds of tests from a finger prick” collapses several distinct claims into one. The number of assays said to have been developed is not the number shown to have been run on the Edison, and neither number proves how the company’s full laboratory service actually performed. The court record’s twelve-assay figure is specifically about assays run on the Edison; it should not be enlarged into a claim about everything Theranos developed or tested.
How did the service operate in practice?
The intended model joined a small sample, a proprietary analyzer and a result delivered as a clinical test. In practice, the company’s laboratory also used commercial instruments. That difference is important: a patient-facing service may offer many tests even when no single machine performs them all. The machine used for one test can differ from the one used for another, and evidence about one instrument should not automatically be applied to every test in the laboratory.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11The record also describes demonstrations that did not represent the apparent use of the device. In demonstrations to visitors, the Edison ran a “null protocol” rather than testing the visitor’s blood, according to evidence summarized in the HHS decision. That fact concerns what happened in those demonstrations; it does not mean that every Edison run was a null protocol. It does, however, show why a demonstration cannot be treated as proof of a complete clinical testing workflow unless the test being shown is actually performed.
For a clinical result to be useful, it is not enough for an instrument to produce a number. A laboratory must have reason to trust that the method works for the sample and test in question, and must monitor whether the process is operating acceptably. Quality-control checks are one way laboratories look for problems before relying on results. The official record reports that Theranos employees said the Edison consistently failed quality-control checks and could not provide accurate results. CMS later identified serious practice deficiencies involving both Edison tests and tests run on modified commercial devices. Those findings point to a laboratory-wide problem, not merely a question of whether one proprietary machine could run a particular assay.
Why did the Edison fail?
The strongest supported explanation is a combination of limitations, rather than a single established engineering cause. The HHS decision issued in 2026 summarizes evidence that the analyzer had accuracy and reliability problems, performed a limited set of tests, was slower than some competing devices, and could not compete with conventional machines for high-throughput testing. Employees testified that it consistently failed quality-control checks and could not provide accurate results. The record does not identify one biochemical or engineering mechanism as the universal cause.
Accuracy and reliability
Clinical testing requires results that are dependable enough for the intended use. The HHS decision’s summary of the trial and appellate evidence describes accuracy and reliability problems with the analyzer, alongside employee testimony about failed quality-control checks. It does not provide a general accuracy percentage or an error rate that can responsibly be quoted for all Edison tests. Without a supported figure, the meaningful conclusion is qualitative: the record describes serious reliability concerns, not a measured rate that applies uniformly across every assay or patient result.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Limited test range
The Edison’s documented use was narrow compared with the broad range of testing associated with Theranos’s public pitch. The appellate record’s figure—twelve assays ever run on the device—helps quantify that gap. It should not be mistaken for a complete measure of the company’s test menu, because other tests were performed on commercial machines. Nor does it show that each of the twelve assays was routinely or successfully used in patient testing.
Throughput
High-throughput testing is about how much testing a system can handle in a given period, not simply whether it can run a test at all. The HHS decision summarizes evidence that the Edison was slower than some competing devices and could not compete with conventional machines for high-throughput testing. The official material cited here does not provide a standardized head-to-head timing table, so it does not support a precise speed ratio. It does support the practical point that the Edison was not shown to match conventional systems on throughput.
Dependence on other instruments
Using commercial analyzers for other tests is not, by itself, proof that a laboratory’s results were invalid. It does mean the proprietary analyzer did not perform the entire service. In Theranos’s case, the record says some commercial devices were modified, and CMS’s inspection findings included quality-control problems involving tests run on modified commercial instruments as well as Edison tests. That broadens the failure beyond a narrow “Edison versus conventional machine” comparison: the laboratory procedures governing more than one kind of equipment were at issue.
Taken together, the supported explanation is that the Edison had a limited demonstrated assay range, serious reliability and quality-control problems, and throughput limitations, while the company relied on commercial analyzers for many other tests. The records establish these connected weaknesses; they do not establish a single technical fault as the explanation for all of them.
Rank #3
- Brand New in box. The product ships with all relevant accessories
What did regulators and the courts find?
CMS’s late-2015 inspection found deficiencies in Theranos’s clinical laboratory practices and procedures that presented “immediate jeopardy” to patient health. The phrase is CMS’s conclusion as quoted in a judicial appendix. It is a regulatory finding about laboratory practice, not a scientific description of a particular Edison component. The cited record specifies that quality-control concerns involved both tests run on the Edison and tests run on modified commercial devices.
Legal allegations, evidence and verdicts should also be kept distinct. The Department of Justice’s case page summarizes indictment allegations that included unreliable results for specific tests. An allegation in an indictment is not, by itself, a finding that a defendant was convicted of that conduct. The HHS decision summarizes trial and appellate evidence about device reliability, use of third-party instruments and investor demonstrations; it is not a substitute for the jury’s verdict on each charge.
Holmes was convicted on investor-related counts. She was acquitted on the patient-related conspiracy count and three patient-fraud counts. It is therefore inaccurate to say that Holmes was convicted of defrauding patients. The device and laboratory evidence can be described without turning allegations into verdicts or treating the criminal outcome as a blanket ruling on every technical claim.
What happened after the testing problems came to light?
The consequences unfolded across 2016 and 2017. The Arizona district court’s 2023 order records that Theranos voided two years of Edison test results on May 18, 2016. Walgreens terminated its agreement with Theranos on June 12, 2016. CMS later revoked the California laboratory’s certificate in July 2016 and the Arizona laboratory’s certificate in February 2017.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errors| Date | Event in the official record | Why it matters |
|---|---|---|
| Late 2015 | CMS inspection found laboratory practice deficiencies presenting “immediate jeopardy” to patient health. | The regulator’s concerns covered laboratory practices and quality control, not just the public claims about the proprietary analyzer. |
| May 18, 2016 | Theranos voided two years of Edison test results, according to the Arizona district court’s 2023 order. | The decision concerned a defined period of results; the cited order does not turn that fact into a quantified error rate. |
| June 12, 2016 | Walgreens terminated its agreement with Theranos, as recorded in the Arizona court order. | This marks the end of that commercial relationship, not by itself a technical finding about every test. |
| July 2016 | CMS revoked the California laboratory certificate. | The company’s laboratory operation faced regulatory consequences after the inspection findings. |
| February 2017 | CMS revoked the Arizona laboratory certificate. | The regulatory consequences extended to the Arizona laboratory as well. |
Voiding results, losing a commercial relationship and having laboratory certificates revoked are different events with different meanings. The first concerns prior test results; the second concerns a business agreement; the third concerns CMS’s authority over laboratory certification. Taken in sequence, they show how the problems moved from technical and laboratory concerns into practical and regulatory consequences. The dates do not establish that every patient result was wrong, and the record cited here supplies no overall error percentage.
What can be said—and what remains unproven?
The public story was a proprietary, small-sample testing system. The court and government record presents a more complicated operation: only twelve assays were ever run on the Edison according to the Ninth Circuit record reproduced in the 2026 Supreme Court appendix; commercial analyzers were used for other general chemistry tests; the Edison faced reliability, quality-control and throughput problems; and CMS found serious laboratory practice deficiencies that involved multiple kinds of equipment.
That account does not reveal the Edison’s full internal design, establish the chemistry used in each assay, or identify one universal mechanical or biochemical failure mechanism. It also does not justify turning the 300 small-sample assays Theranos said it developed into 300 assays run on the Edison. The most defensible explanation is about the gap between claim and demonstrated operation: a broad promise was not matched by evidence that the proprietary analyzer could reliably and efficiently perform that breadth of clinical testing, while the actual service depended substantially on other laboratory instruments and was itself subject to serious quality-control findings.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
